Dr Rupert Jones, Clinical Research Fellow, Centre for Clinical Trials and Population Research, Plymouth University Peninsula School of Medicine and Dentistry, Plymouth; and GP at Armand Surgery Plymouth, UK
- David Price, Centre of Academic Primary Care, University of Aberdeen, Aberdeen, Scotland.
- Niels H. Chavannes, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands.
- Amanda Lee, Department of General Practice and Primary Care, University of Aberdeen, Aberdeen, Scotland.
- Björn Ställberg, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden.
- Karin Lisspers, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden.
- Josefin Sundh, Department of Respiratory Medicine, Örebro University Hospital, School of Health and Medical Science, Örebro University, Örebro, Sweden.
- Michael Hyland, School of Psychology, Plymouth University
On behalf of the UNLOCK group of the IPCRG.
- UNLOCK Group of the IPCRG
- The Respiratory Effectiveness Group
Global Obstructive Lung Disease (GOLD) categories for chronic obstructive pulmonary disease (COPD) are recommended for severity assessment in clinical care. There is a need to understand their value in routine clinical settings and compare them with other multidimensional assessment measures.
An observational cohort study using databases comprising 5486 primary care COPD patients from UK Sweden, and Holland.
The GOLD categories, DOSE and ADO indices, associations with (i) current health status measured by the CCQ and SGRQ; exacerbations and hospital admissions and (ii) future exacerbations, admissions and mortality. The distribution into GOLD categories and future risk associated with the categories.
Documents and Publications